Infinity Pharmaceuticals (INFI) is a drug discovery and development company based in Cambridge, MA.
The company's lead product is IPI-145, being developed for both Hematologic malignancies and Inflammation. Investor's focus is firmly on IPI-145 and its potential in various types of blood cancer (CLL, iNHL, MCL, T-Cell). IPI-145 is a potent, oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K).
What are PI3Ks?
PI3Ks are a family of enzymes involved in key immune cell functions. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and non-overlapping roles in key cellular functions, including cell proliferation, cell differentiation, cell migration and immunity. Therefore, inhibition of PI3K-delta and PI3K-gamma may have...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: